A Study of RD14-01 in Patients With Advanced Solid Tumors
NCT05638828 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2022-12-06
Summary
This study will evaluate the safety and tolerability of RD14-01, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ advanced solid tumors.
Conditions
Interventions
- DRUG
-
RD14-01 Cell injection
RD14-01 Cell injection
Sponsors & Collaborators
-
Shen Lin
lead OTHER
Principal Investigators
-
Lin Shen, Prof. Dr. · Peking University Cancer Hospital & Institute
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-12-01
- Primary Completion
- 2023-12-01
- Completion
- 2024-12-01
More Related Trials
-
Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
NCT05387226 ·Status: UNKNOWN ·Phase: PHASE1
-
KSH01-TCRT Solid Tumors
NCT05539833 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
NCT05909527 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells
NCT06586658 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors
NCT04467853 ·Status: TERMINATED ·Phase: PHASE1
-
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies
NCT04008394 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
NCT07093086 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
NCT06383507 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
NCT03576807 ·Status: UNKNOWN ·Phase: PHASE1
-
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
NCT07275853 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies
NCT05923541 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT06655519 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors
NCT05947487 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
NCT05105867 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours
NCT06238336 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
NCT04004637 ·Status: UNKNOWN ·Phase: PHASE1
-
CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia
NCT04785833 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis
NCT05477446 ·Status: UNKNOWN ·Phase: PHASE1
-
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
NCT05618041 ·Status: RECRUITING ·Phase: NA
-
Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors
NCT06849921 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
NCT06732492 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
NCT05472857 ·Status: RECRUITING ·Phase: PHASE1
-
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
NCT04689659 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.
NCT07244380 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
NCT05683717 ·Status: RECRUITING ·Phase: PHASE1